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Abstract
Background: The Specialized Program of Research Excellence (SPORE) in Head and Neck Cancer
neoplasm virtual biorepository is a bioinformatics-supported system to incorporate data from
various clinical, pathological, and molecular systems into a single architecture based on a set of
common data elements (CDEs) that provides semantic and syntactic interoperability of data sets.
Results: The various components of this annotation tool include the Development of Common
Data Elements (CDEs) that are derived from College of American Pathologists (CAP) Checklist and
North American Association of Central Cancer Registries (NAACR) standards. The Data Entry
Tool is a portable and flexible Oracle-based data entry device, which is an easily mastered web-
based tool. The Data Query Tool helps investigators and researchers to search de-identified
information within the warehouse/resource through a "point and click" interface, thus enabling only
the selected data elements to be essentially copied into a data mart using a multi dimensional model
from the warehouse's relational structure.
The SPORE Head and Neck Neoplasm Database contains multimodal datasets that are accessible
to investigators via an easy to use query tool. The database currently holds 6553 cases and 10607
tumor accessions. Among these, there are 965 metastatic, 4227 primary, 1369 recurrent, and 483
new primary cases. The data disclosure is strictly regulated by user's authorization.
Conclusion: The SPORE Head and Neck Neoplasm Virtual Biorepository is a robust translational
biomedical informatics tool that can facilitate basic science, clinical, and translational research. The
Data Query Tool acts as a central source providing a mechanism for researchers to efficiently find
clinically annotated datasets and biospecimens that are relevant to their research areas. The tool
protects patient privacy by revealing only de-identified data in accordance with regulations and
approvals of the IRB and scientific review committee.
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Due to advances in cancer diagnostics and therapeutics
over the past few decades, the complexity of these areas
has increased and the treatment and management of can-
cer patients has become even more of a challenge. Growth
in translational research, focused on the identification
and validation of disease biomarkers, has led to the devel-
opment of biorepositories that are capable of providing
high quality biospecimens with detailed clinical annota-
tions. Recent developments in information technology
have been an important enabling factor in this process by
providing the basis for an informatics architecture that
can carry out and harmonize many of the functions that
biorepositories need to perform. Informatics as a disci-
pline involves the collection, classification, storage,
retrieval and dissemination of recorded knowledge [1].
Over the last decade, the development of tissue banking
and informatics systems has been recognized as crucial to
the pursuit of detailed translational cancer research. How-
ever, it also has the potential to truly transform systems:
the basic observation of the information age is that the
sharing and dissemination of knowledge does not dimin-
ish its value, but can actually create new synergies and
applications of that knowledge by increasing its utiliza-
tion and accelerating the rate of advances. In order to truly
take these systems into the information age, semantic and
syntactic interoperability across multiple institutions
must be achieved, which requires a robust system of clin-
ical annotation based on controlled vocabulary and
ontology [2]. The recommendation in the RAND Corpo-
ration's Case Study of Existing Human Tissue repositories,
"...the collection of consistent and high quality data asso-
ciated with every biospecimen and employing a standard-
ized set of common data element for annotation..." is now
broadly considered best practice: this general consensus
reflects the need for such standardization [3-5]
The head and neck cancer virtual biorepository is funded
through a Specialized Program of Research Excellence
(SPORE) grant (P50) mechanism, which promotes inter-
disciplinary research involving both cancer patients and
populations at risk for cancer. SPORE investigators work
collaboratively to plan, design and implement research
programs that may impact cancer prevention, detection,
diagnosis, and treatment. Additionally, the SPORE pro-
gram supports collaborative efforts within the individual
multidisciplinary SPORE teams, inter-SPORE collabora-
tions, partnerships with other NCI/NIH programs, and
public-private partnerships with industry and non-profit
organizations. Important characteristics of the program
are the inclusion of patient advocates in SPORE activities
and international cooperation with investigators in
Europe, Canada, Asia, and Mexico. SPOREs in Head and
Neck (H&N) cancer support translational research on can-
cers of the upper aerodigestive tract and thyroid cancer.
The SPORE head and neck cancers program was estab-
lished in the year 2001, with three new SPORE programs
established and funded in the year 2002, the fourth in
2004, and the 5th in 2007.
In this manuscript we will describe the contribution of the
Department of Biomedical Informatics at University of
Pittsburgh in the development and implementation of a
bioinformatics infrastructure developed on a set of com-
mon data elements to integrate data from various clinical,
pathologic and molecular resources into one design in
order to support basic science and clinical as well as trans-
lational research. The use of common data elements
(CDE) provides semantic and syntactic interoperability
across multiple hospital data resources. Common Data
Element sets were developed by mutual consensus among
professionals using the North American Association of
Central Cancer Registries (NAACR) [6] standards and Col-
lege of American Pathologists (CAP) protocol and check-
list [7].
The virtual biorepository provides web-based data entry
and data query tools. The clinical annotation warehouse
system is supported in a Java-based three-tiered architec-
ture. It also provides image storage and analysis tools, in
addition to serving as a data warehouse for clinicopatho-
logical and follow-up datasets. The resource allows inves-
tigators to utilize the warehouse to obtain high quality
clinically annotated biospecimens for clinical and transla-
tional cancer research. The query tool accesses the central
database through a highly constrained "click and point"
interface. The resource will have no access at any time to
patient identified data and tissue will only be made avail-
able to researchers upon user authorization. Furthermore,
by integrating multimodal datasets in the annotated tissue
repository, and making this information available
through the creation of query and visualization tech-
niques for these diverse data types, this provides better
characterized tissues for research and allows users to select
them with a greater degree of flexibility.
Methods
Standard for Subject Enrollment/Exclusion
All participants enrolled in the SPORE Head and Neck
Neoplasm Project (Epidemiology of Genetic Susceptibil-
ity to Head and Neck Cancer) are consented and enroll-
ment criteria are based on following inclusion/exclusion
protocols:
Case definition
The inclusion and exclusion criteria, used to define the
case series, appear below.Page 2 of 17
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I. Age 18-79 years on date of first diagnosis of qualify-
ing head and neck cancer. Biopsy proven primary
squamous cell cancer at a head and neck site. For the
purposes of this research, head and neck cancer sites
include primary tumors coding to Chapter 3 (Lip and
Oral Cavity), Chapter 4 (Pharynx, including base of
tongue, soft palate, and uvula), Chapter 5 (Larynx), or
Chapter 6 (Nasal Cavity and Paranasal Sinuses) of the
American Joint Committee on Cancer (AJCC) Staging
Manual (6th edition) [8].
II. Study enrollment based on acquisition of informed
consent and collection of questionnaire data at the
time of diagnosis or after one year from the initial
diagnosis of the qualifying head and neck cancer.
Exclusion criteria (case series)
I. Age less than 18 years on date of first diagnosis of
qualifying head and neck cancer.
II. Age more than 79 years on date of first diagnosis of
qualifying head and neck cancer.
III. Absence of a clinical pathology report document-
ing invasive cancer involving a head and neck site.
IV. Histopathologic diagnosis other than squamous
cell carcinoma.
V. More than one year elapsed time since date of first
biopsy diagnosis of most recent primary squamous
cell carcinoma at a head and neck cancer site.
Diagnoses are subject to verification by a pathologist. The
investigators will remove a participant from this research
study if the final pathology report does not confirm a pro-
visional diagnosis used for study enrollment purposes. If
the final pathology report does not demonstrate primary
squamous cell carcinoma of the head and neck, the inves-
tigators will remove the participant from the study and
his/her data and blood, urine, and saliva sample will be
rendered anonymous and destroyed.
Control definition
The inclusion and exclusion criteria, used to define the
control series, appear below.
Inclusion criteria (control series)
Age 18-80 years on date of enrollment.
No personal history of cancer at a head and neck site
(based on eligibility screening interview and/or review of
ENT or Dental Clinic medical record).
I. (If a clinic control) Clinical examination (by per-
sonal ENT physician or dentist), without clinical sus-
picion of head and neck cancer, based on testimony of
clinician or review of primary medical records.
Exclusion standards (control series)
I. Age less than 18 years on date of enrollment.
II. Age more than 80 years on date of enrollment.
III. Subject self-report of personal history of cancer at
a head and neck cancer site.
IV. (If a clinic control) Indication in ENT or dental
clinic record of personal history of cancer at a head
and neck cancer site.
V. (If a clinic control) Physical findings, on head and
neck clinical examination, that creates a suspicion of
cancer at a head and neck cancer site.
SPORE Head and Neck: Tissue Bank
Eligibility standards
I. Participants under the care of doctors in the Depart-
ment of Otolaryngology at the University of Pitts-
burgh, as well as healthy controls who are not under
the care of our doctors will be accrued.
II. Participants who are at risk for or have developed
primary, recurrent, metastatic or second primary can-
cer of the head and neck will be enrolled. In addition,
people with a non-cancerous diagnosis, who may or
may not be having surgery, will be asked to participate
as controls.
III. Any age 18 years or older. Children are not
included since the incidence of head and neck cancer
in individuals under the age of 18 is remarkably rare.
IV. Written and informed consent will be obtained.
Mentally-impaired adults or those are not capable of
understanding the consent information will not be
included in this research project.
Standards for Data Collection and De-identification
Development of Common Data elements (CDE)
Common data elements are developed to facilitate anno-
tation of cases at epidemiology, demographics, clinicopa-
thology and follow-up status. CDEs also provide
characterization of biospecimens collected at University
of Pittsburgh Medical Center (UPMC). The CDEs encom-
pass cancer registry data (treatment, vital status, recur-
rence etc) at the case level. CDEs provide specimen level
pathology data elements to describe tumor staging grade
and histological type, along with genotype data elementsPage 3 of 17
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data collection were developed from several sources,
including the North American Association of Central Can-
cer Registries (NAACCR)[6] and College of American
Pathologists (CAP) [7] cancer protocol and checklist, and
the Association of Directors of Anatomic and Surgical
Pathology (ADASP)[9] and American Joint Committee on
Cancer (AJCC) [8] cancer staging manuals. This was
achieved through the combined efforts of domain experts
from various specialities using core standards under the
supervision of the SPORE Head and Neck Neoplasm
Biorepository coordinating committee. The CDEs devel-
oped are ISO/IEC 11179 (International Standards Organ-
ization/the International Electrotechnical Commission)
compliant. CDEs define a number of fields and relation-
ships for metadata registries, including a metadata model
for defining and registering items, of which the primary
component is a data element [10].
The informatics supported architecture allows the CDEs
that are used to annotate the biospecimens to be semanti-
cally and syntactically interoperable by describing them in
the form of metadata or data descriptors. The individual
CDEs are associated with an attribute of an object or con-
cept, and valid value or values. For example, "patient age
at diagnosis" is the CDE that consists of "patient" as an
object, "age at diagnosis" as an attribute and the represen-
tation value domain in "years". To collect data based on
approved CDEs, the data managers need to know the fun-
damental definition of the data element, standards of data
collection, mutually accepted values or codes for the data
element, and the acceptable data format for inclusion in
the central database. Although the concept of formalized
metadata is fairly straightforward, it has rarely been taken
into account by clinical and research groups building
databases [11].
Data Collection, Development of Data Collection Application and 
Data Transmission
The research nurse coordinator is responsible to consent
the patient at the time of physician office visit before the
surgery or undergoing surgical procedures. At the time of
consent self-administered questionnaires are handed over
to the patient to collect information on demographics,
risk factor exposures including tobacco and alcohol use,
sexual behavior and previous medical history. Structured
pathology data is retrieved from the coPath system plus
application (Version 3.0.2.74 Cerner DHT, Inc.) in the
form of synoptic reports. The surgical pathology report
and all histological sections available to the head and
neck pathologist are reviewed to correctly categorize each
case. The pathologist then selects representative slides and
paraffin blocks according to a study standardized proto-
col. The selected slides show specific features of the case
likely to be of interest for scientific investigators. After the
pathological data are reviewed, the certified tumor regis-
trars review and extract clinical and follow-up data. The
data are collected through the cancer registry information
system (CRIS) or manually from the patient medical
charts. Collected data are then stored by using common
web-based data entry forms that are correlated with the
CDEs developed within the head and neck neoplasm
organ specific database.
De-identification Process and Honest Broker Concept
The SPORE in head and neck cancer virtual biorepository
is structured to protect patient privacy and confidentiality
according to Institutional Review Board (IRB) regulations
and HIPAA (Health Insurance Portability and Accounta-
bility Act) approved protocols. The database discloses
only deidentified patient information and displays no
links to patient identifiers (name, date of birth, procedure
date, therapy date, etc). The only linkage is kept within the
institution and the database generates de-identified data-
set upon query by the end users (the so-called "safe har-
bor" approach to HIPAA compliance) [12]. The "safe-
harbor" approach involves exclusion of all 18 identifiers
enumerated in section 164.514(b) (2) of the regulations.
Thus for example, a participant's age is presented as age
range, rather than the date of birth, and therapy dates are
provided in months from first positive tissue diagnosis to
therapy start date rather than presenting a precise calendar
date. These are some of the measures adopted to protect
the identity of patients while still providing sufficient
information for research purposes. All data requests are
tracked in the secure SPORE Head and Neck Neoplasm
Database regardless of whether the purpose is clinical or
research related.
The de-identification process is performed by an honest
broker, which acts as a filter between completely identi-
fied confidential clinical patient information and the
completely de-identified data made available to the
research community. An honest broker is an individual,
organization or system acting on behalf of the covered
entity to collect and provide health information to the
investigators in such a manner whereby it would not be
reasonably possible for the investigators or others to iden-
tify the corresponding patients/subjects directly or indi-
rectly. The honest broker cannot be one of the
investigators or researchers. A researcher may use the serv-
ices of an honest broker service to obtain the Protected
Health Information in a de-identified manner. The honest
broker service will de-identify medical record information
by automated or manual methods. All honest broker serv-
ices are approved in advance by both the IRB of record
and University of Pittsburgh Medical Center (UPMC). If
an honest broker service is not part of the UPMC covered
entity, a valid business associate agreement with UPMC is
executed with UPMC in order to access UPMC-held Pro-Page 4 of 17
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est broker service is to be used to obtain de-identified
Protected Health Information, this fact must be identified
in the study's IRB submission. The honest brokers in this
case are individuals who have clinical responsibilities as
tissue bankers in the Health Sciences Tissue Bank (HSTB),
postdoctoral fellows who manage the pathology data or
cancer registry specialists in the UPMC Network Cancer
Registry. Based on their clinical job duties, their educa-
tional backgrounds and experiences vary. Depending on
the nature of the projects, these bankers can work auton-
omously or collaboratively to meet biospecimen and data
needs [13].
Accuracy Assessment of Multimodal Datasets
The SPORE Head and Neck Neoplasm Database has col-
lected essential information, such as patient demo-
graphic, pathology, treatment, recurrence and risk factor
exposure data, from head and neck neoplasm patients at
the University of Pittsburgh Medical Center since 1980.
After importing the multimodal data into the head and
neck organ specific database, accuracy is assessed by
trained and certified personnel, using policies, variable
constraints, and logical tests established by the resource.
Data are collected by the data managers from electronic
sources including the Medical Registry System (MRS),
pathology reports from coPath Plus and the social security
death index for entry into the database. The evaluation of
the collected data is done using the following approach.
The first step is to evaluate discrepancies between the data-
base quality check curators. The primary focus of data
accuracy assessment is on tumor record, staging, histol-
ogy, diagnosis, treatment, recurrences and risk factor
exposure data. The selected data fields are categorized on
separate error rate for primary, secondary and tertiary pri-
ority fields. The error rate for each case is calculated
depending upon number of discrepant entries and the
number of fields evaluated for a case. Evaluated number
of fields and number of discrepant entries for selected
cases are used to find the error rate for each discrete prior-
ity level data field.
The second step evaluates the accuracy of database entries
by comparing them to the electronic data source from
which data are collected. Data fields have been divided
into high priority, secondary priority, and tertiary priority.
For those fields listed as either high priority or secondary
priority, the number of deviations from the entry per total
number of high priority fields assessed will yield an esti-
mate of the error rate for each priority tier. For high prior-
ity fields, which include patient demographic and clinical
data and tumor pathologic data, the estimated error rate
should not exceed 2%. For secondary priority fields,
which include risk factor data, there is a slighter higher
allowed rate of 5%. The high priority fields are composed
largely of fields extracted from the UPCI tumor registry.
The UPCI tumor registry guidelines require that the error
rate not exceed 3%. A threshold of 2% was selected for
high priority fields as a compromise between a desire for
a research quality database with an error rate less than 1%
and the practicality of the resources and effort already
required to meet the mandated less than 3% error rate
guideline. A less than 5% error rate was estimated to pro-
vide reasonable quality risk factor exposure data, which
have been collected using instruments that have varied to
some degree over the time period of collecting of these
data. An error rate will also be calculated for tertiary fields;
however, no threshold has been set for the tertiary field
error rate to initiate a database update. Initially, 1% of the
subjects are evaluated. If discrepancies are within error
rate guidelines for primary and secondary fields, a further
5% of subjects will be randomly selected using the same
strategy, and estimated database error rates will be calcu-
lated separately for the first and second priority fields for
the 5% sample. If the error rate guidelines are not met for
the 1% initial evaluation, a careful analysis of the differ-
ences will be performed and discrepancies identified. A
quality check of all database subjects will be performed,
focusing on discrepant fields. After the quality check has
been completed, a second sampling of 1% of subjects will
be performed. This sampling will exclude subjects sam-
pled in the prior evaluation. Error rates will be deter-
mined, and if error rate guidelines are met, a further 5% of
subjects will be evaluated using the same criteria.
The third step involves comparing the data in the database
to data in primary sources such as clinical charts and
pathology reports. Subject sampling will be performed
and data field error rates will be calculated as above. How-
ever, due to the amount of time and effort required to
review primary records, only 1% of database subjects will
be evaluated. In order to best identify differences in elec-
tronic versus primary data, these 1% of subjects will be a
randomly selected subset of the 5% of subjects assessed
for consistency with the electronic database.
Accuracy Assessment of pathological data
The pathology data pertaining to each case of paraffin-
embedded tissue block e is entered after complete assess-
ment by trained head and neck pathologists. This is an
independent review process in which a series of randomly
selected cases are re-reviewed. The data managers ran-
domly select cases for independent review from those
added to the head and neck neoplasm database within
certain cut-off dates. The independent review material
consists of 2 to 5 pathologic matrix slides, defined as
slides selected for annotation, for each case. Once the
pathologist receives the slides, he/she will evaluate and
annotate the matrix slides and histology CDE data for thePage 5 of 17
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then scrutinize the histology CDE data for observer varia-
bility and diagnostic error rates. This process occurs bian-
nually and is established to check specimen resource
quality. Any discrepancies identified through independ-
ent review are communicated to the pathology subcom-
mittee. The pathology subcommittee then discusses these
findings in the subsequent general meeting of the coordi-
nating committee through a formal report with recom-
mendations for changes in process as indicated by the
independent review findings. Any errors discovered dur-
ing the independent review process are corrected [14].
SPORE Head & Neck Neoplasm Database
Integrated Informatics Modal
The overall system is designed as a multi-tiered applica-
tion using Oracle 10 g Database Server, Oracle 10 g Appli-
cation Server, and MOD_PLSQL, also known as PL/SQL
Server, on a Compaq DL360 Server running Win2K with
SP. This application utilizes the Oracle HTTP Server and
MOD_PLSQL extensions to generate dynamic pages from
the database to the users. The database is Oracle 9.2.0.1
Enterprise Edition implemented on a SunFire V880 Server
running Solaris 2.8. Approximately four months period of
time was spent in the development and deployment of the
initial application set up. Application enhancement and
expansion are continuous process that is carried out based
upon end user requirements.
The informatics model depicts the SPORE Head and Neck
Neoplasm Database in the following layers: Schema layer -
this consists of concrete data and data relations. All classi-
fied data is stored as numbers and keys. Metadata layer -
demonstrates data in terms of data elements and "groups
of data elements". Data descriptions such as data
attributes, display attributes, valid values, DB Link, valida-
tion rules and documentation are supported in metadata.
The Metadata layer defines the application layer. Proce-
dures/function layer - depicts a set of dynamic functions (in
PL/SQL or Java) with control data transformation at the
back end. The procedures accommodate changes in the
metadata and immediately reflect the changes in the
application layer. Application layer (Form builder) - presents
a set of "applications" including the metadata dictionary
builder and manager, user management, data entry/trans-
fer, query, display, etc. The appearance may differ depend-
ing on user privileges. These differences are driven by the
metadata and user management.
SPORE Head and Neck Neoplasm Database Model
The SPORE Head and Neck Neoplasm Database consists
of the following integrated application layers that main-
tain data query/entry, data de-identification and the user
management module (Figure 1).
i. Presentation Layer
This contains the following components: metadata
curation is used by data administrators and CDE cura-
tors for registering new CDEs or editing definition of
existing CDEs. The administrator security system is used
by the application administrators to grant, revoke or
limit privileges to new and existing users. Manual
annotation is used by honest brokers or domain experts
for collecting information regarding patients regis-
tered for the study. Data query is used by the honest
brokers and research community to run criteria based
queries. The query results show identified and de-
identified outputs depending on the individual roles
and privileges granted by application administrators.
This tool provides two levels of access to researchers
who participate in the SPORE Head and Neck neo-
plasm study. The first level of access is to have broker
view of the consented patients for their own study and
second is a de-identified view on all the patients for
other studies for which they do not have access but
want to study and analyze overall trends. The data
import/export component provides users an option to
electronically import preformatted data from existing
systems or export data for their desktop analysis (Fig-
ure 2).
ii. Metadata Engine
The Metadata Engine is based on the development of
Common Data Elements that are used to hold applica-
tion data structure for data elements/fields as defined
by the SPORE Head and Neck Neoplasm Project work-
ing group. The HELP builder is used for each data ele-
ment/field with its detailed definition of business
rules and usage. The business rules engine constitutes
business rules for how multiple elements can be com-
bined with simple numerical and algorithmic tech-
niques to report complex values for decision support
and statistical time sensitive outputs. The mapping
engine maps logical and physical layers of design that
facilitate data retrieval and storage (Figure 3).
iii. Security Engine
The security engine secures the application at three lev-
els: the first is registration of new user accounts and
requesting application roles. Second is authentication
byadding/editing user information, and lastly, author-
ization is granting or revoking user roles and privileges.
iv. Physical Data
The physical database tables are presented in the data
warehouse in a three step fashion. First is the applica-
tion database that holds case data contents in a meta-
data coded format. Second is the metadata database,
which holds metadata definitions and descriptions for
all the attributes and values in the system. The thirdPage 6 of 17
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Presents the actual data model architecture for Organ Specific data warehouse implementation for head and 
Neck SPORE program. This architecture supports data query and data entry and data de-identification and user manage-
ment module.
BMC Cancer 2009, 9:396 http://www.biomedcentral.com/1471-2407/9/396one is a security database which drives the security and
authorizations definitions and assignments.
Results
The Head and Neck Neoplasm Database contain over
6553 archived and prospective head and neck neoplasm
cases. Biospecimens that are collected from over 10607
surgical resections and biopsies, as well as whole blood
and DNA samples, are included in the resource. The
majority of these cases consist of archival paraffin blocks
from surgically treated patients.
The SPORE Head and Neck Neoplasm common data ele-
ments (CDE) are developed using previously described
standards (NAACCR, ADASP & CAP) for building CDE
datasets. A multi-tiered application using Oracle 10 g is
the platform for the web based query tool. Access to the
database is available only to investigators approved by the
IRB and Scientific Review Committee. It permits users to
query the data related to the specimen that they have
received from the resource for their approved studies and
enables them to develop their own case lists. The query
results display only de-identified datasets linked to each
case via pre-defined views.
Work flow for entering the data into the database using 
web based data entry tool
The datasets collected from different sources are manually
entered in the databases by utilizing the data entry tool.
This tool is password protected and controlled by a user
authentication process/manager controlled user manage-
ment module (Figure 4). The local (physical) tissue bank
identifies cases appropriate for inclusion in the Head and
Neck Neoplasm Virtual Bio-repository. All cases entered
into the virtual biorepository are based on interview data
and the complete associated tissue/biopsy data for the
participant. The local tissue bank pre-processes data on
these cases. The most important component of pre-
processing is de-identification. All de-identification
occurs at the local banks. No identifiable data is sent to
Presents the ability to export data query results to Microsoft Excel file format along with query criteria for future analysis and allow users to sort on every data fieldFigure 2
Presents the ability to export data query results to Microsoft Excel file format along with query criteria for 
future analysis and allow users to sort on every data field. Exported data can be deidentified or identified based on use 
access authentication.Page 8 of 17
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into the warehouse through a web site. The data entry web
site uses radio buttons, combo boxes and other highly
constrained data elements. The local banks label each case
with a de-identified number. This number is used to link
the information in the warehouse to the cases in the local
banks. The linkage codes are stored locally, using appro-
priate electronic and physical safety measures. Only the
local banks have access to these linkage codes. The ware-
house contains very minimal demographic data and com-
plies with all HIPAA requirements. Cases entered into the
virtual biorepository are scanned for logical errors (e.g.:
first recurrence before diagnosis etc.).
Workflow for querying the database
Initially, access is limited to members of the SPORE Head
and Neck Neoplasm working group using a user name
and password system. The data administrator can provide
a user name and password for approved researchers or
nursing coordinators to access the tool. The query tool
access to the central database is through a highly struc-
tured "click and point" interface. The data in the database
allows queries on approved data elements and also is
based on the researcher's IRB approval. The specificity of
the data returned depends on the user's profile. There are
four user profiles;
i. Approved Investigator Query tool is a password-
protected application which is distributed to those
research investigators who have approved research
protocols within the SPORE Head and Neck Working
Group. It allows users to refine and compile case lists
for their application and also to mine and modify the
data set on the cases where they have received biospec-
imens. The query tool provides search on all the anno-
tated data associated with each subject through
multiple pre-defined standard views of the data set
and also allows users to customize their own views
and save them under their account (Figures 5, 6 and
7).
Presents the Meta Data Application management interface for developing the metadata common data elements, data descrip-tions, data pres ntation and help documentation building and mapping of dictionary CDE definitions to physical data tables by Application Data Manager and Syste  D sign rFigure 3
Presents the Meta Data Application management interface for developing the metadata common data ele-
ments, data descriptions, data presentation and help documentation building and mapping of dictionary CDE 
definitions to physical data tables by Application Data Manager and System Designer.Page 9 of 17
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tected tool available only for the internal data admin-
istrators. It is meant to be used by data administrators
to address quality assurance issues regarding the data.
The main difference between this and the approved
investigator tool is that this tool allows the user to
search by "all Subjects" or "limited Subjects" based on
consent for a particular study.
iii. Public Query tool is available to the general public
and accessible through the main home page. The out-
put display of a public query will be the accrued
number of cases, specimens in the database that meet
the criteria of the query and general statistics on a lim-
ited number of data elements. It is designed to allow
interested investigators to determine if the resource
will be applicable to their research needs (Figure 8
&9).
iv. Human Papilloma Virus (HPV) questionnaire
and Project-1 Epidemiological data:
The Project-1 interviewer-administered and HPV self-
administered study questionnaires captures patient
epidemiological and sexual behavior information. The
annotation tool provides manual data entry and query
on de-identified information obtained from these
questionnaires through a "point and click" interface
that internally integrates with annotated clinicopa-
thology data sources.
Integration of Multimodal Data Sources
The SPORE Head and Neck Neoplasm Database supports
integration with other prominent sources of patient
related information regarding diagnosis, follow-up, treat-
ment, as well as questionnaire data. The pathology anno-
tation and inventory data of banked tissues are tracked by
the biorepository team by utilizing synoptic reports from
the anatomic pathology information system. The research
registrar and data manager gather follow-up and out-
comes related data by reviewing medical records. The
questionnaire data provides patient epidemiological and
sexual behavior information. This allows the users of this
Presents the User management module for controlling the user access to different applications modules within the data ware-house by Application Data Manager and System AdministratorFigure 4
Presents the User management module for controlling the user access to different applications modules 
within the data warehouse by Application Data Manager and System Administrator.Page 10 of 17
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overall view of the patient's progress and history.
Discussion
The growing importance of translational research and
development of informatics tools capable of analyzing
clinical tissue samples has increased the SPORE research
community demand for high quality and well annotated
biospecimens. To satisfy this demand, the SPORE Head
and Neck Neoplasm working group has established an
integrated head and neck neoplasm biobank and web-
based database query tool. This system is built on an
underlying architecture of common data elements for
characterization of tissue samples and clinical follow-up
data, supported by an essential quality assurance process.
In the development of the SPORE Head and Neck Neo-
plasm Database, experts from various specialized fields
invested a significant amount of time and effort to design
and deploy a high quality and well annotated biospeci-
men resource. In the clinician's domain, the focus was on
creating CDEs that aim at the acquisition of information
adhering to current standards on clinicopathology, follow
up, and cancer outcome. Special consideration in this
regard was given to a future extrapolation of at least five
years during which any data may become clinically signif-
icant. Data from patient questionnaires was also included
in CDE development. The resultant data sets are expected
to satisfy the needs of the SPORE research community and
augment future translational research activities. The can-
cer registries, bioinformaticians and research nurse coor-
dinators who are responsible for data gathering provided
invaluable input regarding metadata and data types in the
process of CDE development.
Presents the metadata driven search query template for the end user to define and build their data query criteria and get the qu ry based resultsFigure 5
Presents the metadata driven search query template for the end user to define and build their data query cri-
teria and get the query based results. In addition multiplex query tab allows to do free text search.Page 11 of 17
(page number not for citation purposes)
BMC Cancer 2009, 9:396 http://www.biomedcentral.com/1471-2407/9/396It is imperative that CDEs and the metadata coupled must
be defined with absolute clarity and made comprehensi-
ble to the people involved in data collection. The aim of
collecting high quality annotated data was realized
through the implementation of ISO 11179 compliance
standards [15]. Despite the fact that it is a rather simple,
clear cut concept, the formalized metadata model has sel-
dom been implemented by research and clinical groups in
the process of data base development. Technical issues
pertaining to CDEs were resolved by the database devel-
opers and informaticians who also designed the architec-
ture for CDE deployment.
This also allows a much closer monitoring of trends and
issues in cancer, which is essential to the ultimate goal of
the NCI, the lessening of the burden of pain and suffering
from cancer [16]. The NIH and NCI strategic roadmaps
clearly define the value of tissue banks and informatics in
supporting these objectives [17].
SPORE head and Neck Neoplasm Database Annotation 
Interface
In the annotation process a data entry web interface is
used for manual entry of all relevant clinical, cancer regis-
try and pathologic information. Strict protocols are main-
tained for integration, de-identification and
standardization during data entry. The integration process
involves collecting prospective data and incorporating ret-
rospective data from multiple clinical systems over time
regarding a selected patient. For example, data must be
gathered from different sources such as the pathology
information system, medical archive system, tissue bank
inventory system and the cancer registry.
Annotation Challenges
There are two major obstacles in this process. First is the
correct identification of a certain patient in multiple sys-
tems or hospitals and the second is pinpointing only
applicable information. In order to track follow-up data
on patients who utilize multiple health care systems, one
Presents Standard data views defined by System Administrator and based upon user selected query criteria; User's have the ability o define their own data views and da a cohortsFigure 6
Presents Standard data views defined by System Administrator and based upon user selected query criteria; 
User's have the ability to define their own data views and data cohorts.Page 12 of 17
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sources. This can be achieved by common linking patient
identifiers or health information; nevertheless discrepan-
cies can occur owing to errors based on data entry issues
or the absence of specific identifiers unique to the
patients. The head and neck neoplasm virtual bioreposi-
tory has applied a solution to address these obstacles
which is mainly a process of manual data collection and
entry by the data managers. This ensures that the focus on
data quality is maintained. However the collected data
that has temporal relationship still requires to be evalu-
ated for context before it can be captured into a database.
The approach was carried out by the resource to tackle
data context that is basically a manual process of data col-
lection and entry. Furthermore this method allows incor-
poration of more data elements than needed for the
resource, including data elements not relevant to head
and neck neoplasm virtual biorepository. These addi-
tional data elements provide integration with other data
sources and verified data integrity. We hope to overcome
such challenges in the future using automated data
retrieval through electronic queries of existing systems
(i.e. MARS and the Pathology Information system). These
would require the use of messaging standards (i.e. HL7
and DICOM), and vocabulary standards (i.e. SNOMED
and UMLS). Despite the effectiveness of these measures
the process may be hampered by the presence of unstruc-
tured systems using free text in lieu of structured data
fields that complicates searching for cases within these
databases. In this scenario manual annotation may be uti-
lized to resolve this issue.
SPORE head and Neck Neoplasm Database Interface
The query tool was designed as a layered web based tool
using an Oracle database platform to share data between
internal members as well as researchers approved by the
IRB and Scientific Review Committee. In addition to its
security features, this query tool enhances the expansion
capabilities for incorporating new data elements or inte-
grating existing system features. Emphasis has been placed
on the ability to define user access level to the datasets,
and we also provide functionality for data monitoring.
The Head and Neck SPORE query tool has the different
Presents the user interface with ability to customize data query result page viewFigure 7
Presents the user interface with ability to customize data query result page view.Page 13 of 17
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ent levels of access.
The public query tool presents part of the data as a public
view because it's available for sharing across the domain
experts. The query tool security layer automatically
reviews the user rights based upon its login information.
Depending upon the user access rights the user's are
allowed to view only that part of the data for which prin-
ciple investigator or system administrators have allowed
access to a particular user. Normally public users are not
allowed to see the actual patient's identifiers' according to
HIPAA rules and regulations. The part of the data is not
even accessed from database tables if users are not author-
ized to see and system masked data fields to the presenta-
tion layer. The public users can still customize their own
data views for export/import purposes but cannot custom-
ize or change the Standard Views or Extended views
(Shared by all levels of users). The standard view displays
the data on subset of collected data like demographic, epi-
demiology tumor accession etc. The extended view dis-
plays the entire data sets collected on all data fields.
In approved investigator query view the users can act as
both Honest Broker and researcher depending upon IRB
consent. In most of these cases IRB-approved researchers
have consent to see patient data for their patients enrolled
in their studies and have honest broker view for data on
these patients. For all other patients the view is masked as
explained earlier in the manuscript. These users can cus-
tomize their own views but can not change/create/delete
the Standard or Extended views of data sets.
Comparison with other Databases Developed Using the 
Identical Technology
The SPORE's Head and Neck Neoplasm Virtual Biorepos-
itory is built on the same technology that is used for
CPCTR and PCABC [18,19], except that an updated ver-
sion of software is incorporated as described in this report.
The data entry in head and neck neoplasm virtual biore-
pository is carried out both by manually utilizing data
Presents the overall statistics for the Head and neck SPORE Data repository and these statistics can be specific to individual qu riesFigure 8
Presents the overall statistics for the Head and neck SPORE Data repository and these statistics can be spe-
cific to individual queries.Page 14 of 17
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which is in similar to PCABC but in contrast to CPCTR
[20]. The Head and Neck Neoplasm Virtual Biorepository
access and utility is currently limited to University of Pitts-
burgh Medical Center researchers who are participating in
the SPORE's head and neck neoplasm project. The SPORE
Head and Neck Neoplasm database has been designed
around the Oracle database and most of the capabilities of
Oracle database server and Oracle application server have
been extensively used. The underlying idea is to improve
the data storage and retrieval process. This tool is generic
in nature and its framework can be used to deploy it for
any other disease specific application since it's architec-
ture is based on three tier data structure (Physical Data
Layer, Meta Data Layer and Presentation Layer as dis-
cussed earlier in this report).
The Physical data layer and Presentation layer or Web
interface codes are all written in PL/SQL server pages and
java scripts to generate dynamic queries and present them
to the front end dynamically generated HTML pages. The
middle layer 'Meta Data Layer' is very much independent
and can be replaced to implement the same structure for
any other organs or disease-specific database application
with similar capabilities, without any changes in under-
written code. This tool is not designed to use technology
like open source/open access but may still be easily
deployed at different sites by having the oracle environ-
ment setup and import the oracle schema framework
copy. The user is anticipated to be able employ this tool
without major technical assistance by following provided
instruction documents. Currently, the Head and Neck
Neoplasm SPORE application tool is being used inter-
nally for UPMC/UPITT users and has not yet been made
available to outside researchers. However, it could be eas-
ily deployed anywhere on windows or UNIX environment
platforms for oracle database 10 g.
The SPORE Head and Neck Neoplasm Database provides
query and data entry interfaces for Project-1 (Epidemio-
logical) and Human Papilloma Virus (HPV) question-
naires and genomic/proteomic data. The database
provides study base access upon user authentication. The
database also provides an inbuilt de-identification option
that is controlled by internal routines and coding mecha-
nisms to mask the data as per HIPPA compliance and pro-
vides access to users based upon their access level and user
Presents statistics on gender, race and cancer type on all head and neck neoplasm casesFigure 9
Presents statistics on gender, race and cancer type on all head and neck neoplasm cases.Page 15 of 17
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cient means of data de-identifications.
The administrator or principle investigator (PI) access to
the Head and Neck Neoplasm Database can have both
honest broker and researcher views with the ability to
view the most of the data fields. The administer or PI has
the ability to create/change/delete/customize Standard
and Extended data views in addition to their own views
and may even change/revoke other user's access rights in
their own group. These options provide both flexibility
and control. This tool was developed in-house and has
been specially designed to support research community
needs not currently met by commercially available tools.
Conclusion
There have been a mounting number of national and
statewide initiatives aimed at supporting the development
of tissue banks promoting the sharing of tissue and data
resources. At present, multiple institute participation is a
feature of several tissue banks including the Cooperative
Prostate Cancer Tissue Resource (CPCTR) [21], Pennsyl-
vania Cancer Alliance for Bioinformatics Consortium
(PCABC) [18], Cooperative Breast Cancer Tissue Resource
(CBCTR) [22], Cooperative Human Tissue Network
(CHTN) [23], Cancer Family Registries (CFR), and the
Early Detection Research Network (EDRN) []. The tech-
nique and means of data and tissue collection vary in each
biorepository, although many of these multi-institutional
collaborations have been compelled to develop principles
for sharing data with other groups due to the pressing
need for well annotated tissues that can be re-annotated
with experimental data.
The established data elements that are used (and often
mandated) in many cancer centers are generally repre-
sented by the synoptic template (CAP protocol and check-
list and WHO standard) and the NAACCR core elements.
In this effort we have demonstrated that the two represen-
tations can be pooled to generate a core set of clinical
annotations for banked head and neck neoplasm speci-
mens. The collection of information for data elements as
been incorporated into the routine hospital workflow so
these data sets can be easily developed and maintained.
The existing array of elements is currently operating in a
database system and we are contemplating means to
establish these elements on ISO/IED compliant data
standard.
The major distinction between The SPORE in Head and
Neck Neoplasm Virtual Biorepository database and most
other tissue resources is that all amassed cases have under-
gone consistent pathology review and the associated clin-
ical data have been carefully collected using a
standardized quality-controlled method. A highly effec-
tive informatics infrastructure has been designed for the
resource that facilitates an efficient governance, standard-
ized data acquisition, and thoroughly standardized case
annotation across multiple participating sites. This infra-
structure includes an operations manual and a database
with common data elements for tissue sample descrip-
tion, clinical follow-up data, and quality assurance proce-
dures.
The web-based query tool allows easy accessibility for IRB-
and SRCB-approved collaborators and researchers. Patient
confidentiality is top priority. A vibrant campaign for mar-
keting of the SPORE resource, which includes a compre-
hensive brochure and an interactive web site, is currently
underway. We hope that this will encourage institutions
and researchers to participate and take advantage of this
extremely valuable resource.
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